Human Papillomavirus and Head and Neck Cancer

Chapter

Abstract

Human papillomavirus (HPV) is a common sexually transmitted pathogen and the primary infectious cause of HPV-related oropharyngeal carcinoma (HPV-OPC). HPV-OPC is distinct in its pathophysiology, epidemiology, and clinical course from HPV-negative head and neck squamous cell carcinoma (HNSCC). The incidence of HPV-OPC has steadily grown over the past several decades. This rise has been attributed to sexual behaviors that increase exposure to HPV. While intensive investigation is clarifying the risk factors and treatment strategies for HPV-OPC, the natural history of carcinogenic HPV infection in HNSCC remains incompletely understood. This chapter provides an overview of carcinogenic HPV infection and the epidemiology of oral HPV infection.

Keywords

Human papillomavirus HPV Oropharyngeal Head and neck Squamous cell carcinoma Oral infection Epidemiology Carcinogenesis 

References

  1. 1.
    Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.  https://doi.org/10.1097/OLQ.0b013e318286bb53. PubMed PMID: 23403598.CrossRefPubMedGoogle Scholar
  2. 2.
    Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16.  https://doi.org/10.1016/S2214-109X(16)30143-7. PubMed PMID: 27470177.CrossRefPubMedGoogle Scholar
  3. 3.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20. PubMed PMID: 10793107.CrossRefGoogle Scholar
  4. 4.
    Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005;11(16):5694–9.  https://doi.org/10.1158/1078-0432.CCR-05-0587. PubMed PMID: 16115905.CrossRefPubMedGoogle Scholar
  5. 5.
    Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407–20.  https://doi.org/10.1093/jnci/djn025. PubMed PMID: 18334711.CrossRefPubMedGoogle Scholar
  6. 6.
    Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.  https://doi.org/10.1038/nature14129. PubMed PMID: 25631445; PubMed Central PMCID: PMCPMC4311405.CrossRefGoogle Scholar
  7. 7.
    Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.  https://doi.org/10.1200/JCO.2011.36.4596. PubMed PMID: 21969503; PubMed Central PMCID: PMCPMC3221528.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.  https://doi.org/10.1093/jnci/djn011. PubMed PMID: 18270337.CrossRefPubMedGoogle Scholar
  9. 9.
    Straetmans JM, Olthof N, Mooren JJ, de Jong J, Speel EJ, Kremer B. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope. 2009;119(10):1951–7.  https://doi.org/10.1002/lary.20593. PubMed PMID: 19650127.CrossRefPubMedGoogle Scholar
  10. 10.
    Agalliu I, Gapstur S, Chen Z, Wang T, Anderson RL, Teras L, et al. Associations of oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident head and neck cancer. JAMA Oncol. 2016.  https://doi.org/10.1001/jamaoncol.2015.5504. PubMed PMID: 26794505; PubMed Central PMCID: PMCPMC4956584.
  11. 11.
    D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199(9):1263–9.  https://doi.org/10.1086/597755. PubMed PMID: 19320589; PubMed Central PMCID: PMCPMC4703086.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11):3282–7. PubMed PMID: 3365707.PubMedGoogle Scholar
  13. 13.
    Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9.  https://doi.org/10.1200/JCO.2013.50.3870. PubMed PMID: 24248688; PubMed Central PMCID: PMCPMC3865341.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, et al. Incidence of oropharyngeal cancer among elderly patients in the United States. JAMA Oncol. 2016;2(12):1617–23.  https://doi.org/10.1001/jamaoncol.2016.1804. PubMed PMID: 27415639.CrossRefPubMedGoogle Scholar
  15. 15.
    Patel MA, Blackford AL, Rettig EM, Richmon JD, Eisele DW, Fakhry C. Rising population of survivors of oral squamous cell cancer in the United States. Cancer. 2016;122(9):1380–7.  https://doi.org/10.1002/cncr.29921. PubMed PMID: 26950886.CrossRefPubMedGoogle Scholar
  16. 16.
    Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–42.  https://doi.org/10.1200/JCO.2015.61.6995. PubMed PMID: 26351338; PubMed Central PMCID: PMCPMC4979086.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human papillomavirus-associated cancers – United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–6.  https://doi.org/10.15585/mmwr.mm6526a1. PubMed PMID: 27387669.CrossRefPubMedGoogle Scholar
  18. 18.
    O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012;48(12):1191–201.  https://doi.org/10.1016/j.oraloncology.2012.06.019. PubMed PMID: 22841677.CrossRefPubMedGoogle Scholar
  19. 19.
    Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017.  https://doi.org/10.3322/caac.21389. PubMed PMID: 28128848.
  20. 20.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.  https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. PubMed PMID: 10451482.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–302. PubMed PMID: 16720315; PubMed Central PMCID: PMCPMC1472295.CrossRefGoogle Scholar
  22. 22.
    Howley PM. On human papillomaviruses. N Engl J Med. 1986;315(17):1089–90.  https://doi.org/10.1056/NEJM198610233151710. PubMed PMID: 3020406.CrossRefPubMedGoogle Scholar
  23. 23.
    Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012;131(9):1969–82.  https://doi.org/10.1002/ijc.27650. PubMed PMID: 22623137; PubMed Central PMCID: PMCPMC3429628.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10.  https://doi.org/10.1016/j.virol.2013.04.023. PubMed PMID: 23683837.CrossRefPubMedGoogle Scholar
  25. 25.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14(2):467–75.  https://doi.org/10.1158/1055-9965.EPI-04-0551. PubMed PMID: 15734974.CrossRefGoogle Scholar
  26. 26.
    Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31.  https://doi.org/10.1016/S1470-2045(14)70471-1. PubMed PMID: 25439690.CrossRefPubMedGoogle Scholar
  27. 27.
    Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747–55.  https://doi.org/10.1002/hed.22015. PubMed PMID: 22267298.CrossRefPubMedGoogle Scholar
  28. 28.
    Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst. 2013;105(8):536–45.  https://doi.org/10.1093/jnci/djt053. PubMed PMID: 23503618.CrossRefPubMedGoogle Scholar
  29. 29.
    Michaud DS, Langevin SM, Eliot M, Nelson HH, Pawlita M, McClean MD, et al. High-risk HPV types and head and neck cancer. Int J Cancer. 2014;135(7):1653–61.  https://doi.org/10.1002/ijc.28811. PubMed PMID: 24615247; PubMed Central PMCID: PMCPMC4107082.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis. 2014;20(5):822–8.  https://doi.org/10.3201/eid2005.131311. PubMed PMID: 24751181; PubMed Central PMCID: PMCPMC4012803.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996;70(5):3298–301. PubMed PMID: 8627814; PubMed Central PMCID: PMCPMC190197.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Guo T, Eisele DW, Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016;122(15):2313–23.  https://doi.org/10.1002/cncr.29992. PubMed PMID: 27152637; PubMed Central PMCID: PMCPMC4956510.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13(7):857–61.  https://doi.org/10.1038/nm1598. PubMed PMID: 17603495.CrossRefPubMedGoogle Scholar
  34. 34.
    Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol. 2012;6(Suppl 1):S48–54.  https://doi.org/10.1007/s12105-012-0371-6. PubMed PMID: 22782223; PubMed Central PMCID: PMCPMC3394160.CrossRefPubMedGoogle Scholar
  35. 35.
    Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32(Suppl 1):S7–15.  https://doi.org/10.1016/j.jcv.2004.12.006. PubMed PMID: 15753007.CrossRefPubMedGoogle Scholar
  36. 36.
    Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68(1):307–13.  https://doi.org/10.1158/0008-5472.CAN-07-2754. PubMed PMID: 18172324.CrossRefPubMedGoogle Scholar
  37. 37.
    Lim MY, Dahlstrom KR, Sturgis EM, Li G. Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinoma. Head Neck. 2016;38(8):1139–44.  https://doi.org/10.1002/hed.24429. PubMed PMID: 27002307.CrossRefPubMedGoogle Scholar
  38. 38.
    Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A. 1995;92(5):1654–8. PubMed PMID: 7878034; PubMed Central PMCID: PMCPMC42578.CrossRefGoogle Scholar
  39. 39.
    Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014;24(2):185–99.  https://doi.org/10.1101/gr.164806.113. PubMed PMID: 24201445; PubMed Central PMCID: PMCPMC3912410.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Sherman L, Jackman A, Itzhaki H, Stoppler MC, Koval D, Schlegel R. Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation. Virology. 1997;237(2):296–306.  https://doi.org/10.1006/viro.1997.8778. PubMed PMID: 9356341.CrossRefPubMedGoogle Scholar
  41. 41.
    Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–36. PubMed PMID: 2175676.CrossRefGoogle Scholar
  42. 42.
    Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497–501. PubMed PMID: 9822382.CrossRefGoogle Scholar
  43. 43.
    Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803–15.  https://doi.org/10.1038/sj.onc.1204252. PubMed PMID: 11313928.CrossRefPubMedGoogle Scholar
  44. 44.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53. PubMed PMID: 1905840.CrossRefGoogle Scholar
  45. 45.
    Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56(20):4620–4. PubMed PMID: 8840974.PubMedGoogle Scholar
  46. 46.
    Ikeda MA, Jakoi L, Nevins JR. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci U S A. 1996;93(8):3215–20. PubMed PMID: 8622916; PubMed Central PMCID: PMCPMC39585.CrossRefGoogle Scholar
  47. 47.
    Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258(5081):424–9. PubMed PMID: 1411535.CrossRefGoogle Scholar
  48. 48.
    Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23.  https://doi.org/10.1038/nature03097. PubMed PMID: 15549093.CrossRefPubMedGoogle Scholar
  49. 49.
    Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403.  https://doi.org/10.1093/jnci/djv403. PubMed PMID: 26823521.CrossRefPubMedGoogle Scholar
  50. 50.
    Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–9. PubMed PMID: 2157286.CrossRefGoogle Scholar
  51. 51.
    Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8(13):4099–105. PubMed PMID: 2556261; PubMed Central PMCID: PMCPMC401588.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990;9(1):153–60. PubMed PMID: 2153075; PubMed Central PMCID: PMCPMC551641.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7.  https://doi.org/10.1038/366704a0. PubMed PMID: 8259215.CrossRefPubMedGoogle Scholar
  54. 54.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.  https://doi.org/10.1056/NEJMoa0912217. PubMed PMID: 20530316; PubMed Central PMCID: PMCPMC2943767.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014;32(35):3930–8.  https://doi.org/10.1200/JCO.2013.54.5228. PubMed PMID: 25267748; PubMed Central PMCID: PMCPMC4251957.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006;344(1):119–30.  https://doi.org/10.1016/j.virol.2005.09.024. PubMed PMID: 16364743.CrossRefPubMedGoogle Scholar
  57. 57.
    Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001;75(9):4283–96.  https://doi.org/10.1128/JVI.75.9.4283-4296.2001. PubMed PMID: 11287578; PubMed Central PMCID: PMCPMC114174.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8(2):209–20.  https://doi.org/10.1128/CDLI.8.2.209-220.2001. PubMed PMID: 11238198; PubMed Central PMCID: PMCPMC96039.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215–22.  https://doi.org/10.1128/CMR.05028-11. PubMed PMID: 22491770; PubMed Central PMCID: PMCPMC3346303.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, et al. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol. 2015;181(1):40–53.  https://doi.org/10.1093/aje/kwu247. PubMed PMID: 25480823; PubMed Central PMCID: PMCPMC4288119.CrossRefPubMedGoogle Scholar
  61. 61.
    Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013;13(12):3202–9.  https://doi.org/10.1111/ajt.12472. PubMed PMID: 24119294; PubMed Central PMCID: PMCPMC4049182.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Lesseur C, Diergaarde B, Olshan AF, Wunsch-Filho V, Ness AR, Liu G, et al. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet. 2016;48(12):1544–50.  https://doi.org/10.1038/ng.3685. PubMed PMID: 27749845; PubMed Central PMCID: PMCPMC5131845.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39(1):166–81.  https://doi.org/10.1093/ije/dyp350. PubMed PMID: 20022926; PubMed Central PMCID: PMCPMC2817092.CrossRefPubMedGoogle Scholar
  64. 64.
    Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcatova I, Merletti F, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol. 2016;45(3):752–61.  https://doi.org/10.1093/ije/dyw069. PubMed PMID: 27197530.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Chaturvedi AK, D'Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. Oral Oncol. 2016;60:61–7.  https://doi.org/10.1016/j.oraloncology.2016.06.006. PubMed PMID: 27531874.CrossRefPubMedGoogle Scholar
  66. 66.
    Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226–35.  https://doi.org/10.1158/1078-0432.CCR-09-2350. PubMed PMID: 20145161; PubMed Central PMCID: PMCPMC2822887.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.  https://doi.org/10.1056/NEJMoa032641. PubMed PMID: 15128894.CrossRefPubMedGoogle Scholar
  68. 68.
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.  https://doi.org/10.1056/NEJMoa032646. PubMed PMID: 15128893.CrossRefPubMedGoogle Scholar
  69. 69.
    Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–8.  https://doi.org/10.1200/JCO.2003.01.008. PubMed PMID: 12506176.CrossRefPubMedGoogle Scholar
  70. 70.
    Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–6. PubMed PMID: 10601378.CrossRefGoogle Scholar
  71. 71.
    Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. Eur J Cancer. 2016;68:125–33.  https://doi.org/10.1016/j.ejca.2016.09.006. PubMed PMID: 27755996.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–22.  https://doi.org/10.3322/caac.21157. PubMed PMID: 22972543.CrossRefPubMedGoogle Scholar
  73. 73.
    de Villiers EM, Lavergne D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer. 1997;73(3):356–61. PubMed PMID: 9359482.CrossRefGoogle Scholar
  74. 74.
    Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol. 1999;9(6):379–86.  https://doi.org/10.1006/scbi.1999.0141. PubMed PMID: 10712884.CrossRefPubMedGoogle Scholar
  75. 75.
    Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005;97(8):577–86.  https://doi.org/10.1093/jnci/dji073. PubMed PMID: 15840880.CrossRefPubMedGoogle Scholar
  76. 76.
    Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.  https://doi.org/10.1001/jama.2012.101. PubMed PMID: 22282321.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Fakhry C, Gillison ML, D'Souza G. Tobacco use and oral HPV-16 infection. JAMA. 2014;312(14):1465–7.  https://doi.org/10.1001/jama.2014.13183. PubMed PMID: 25291584; PubMed Central PMCID: PMCPMC4266546.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004;96(6):449–55. PubMed PMID: 15026470.CrossRefGoogle Scholar
  79. 79.
    Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong ZY, Xiao W, et al. NHANES 2009–2012 findings: association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res. 2015;75(12):2468–77.  https://doi.org/10.1158/0008-5472.CAN-14-2843. PubMed PMID: 25873485; PubMed Central PMCID: PMCPMC4470779.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Kreimer AR, Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Abrahamsen M, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382(9895):877–87.  https://doi.org/10.1016/S0140-6736(13)60809-0. PubMed PMID: 23827089; PubMed Central PMCID: PMCPMC3904652.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012;39(11):860–7.  https://doi.org/10.1097/OLQ.0b013e318269d098. PubMed PMID: 23064535; PubMed Central PMCID: PMCPMC4375438.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Pickard RK, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex Transm Dis. 2012;39(7):559–66.  https://doi.org/10.1097/OLQ.0b013e31824f1c65. PubMed PMID: 22706220.CrossRefPubMedGoogle Scholar
  83. 83.
    Wood ZC, Bain CJ, Smith DD, Whiteman DC, Antonsson A. Oral human papillomavirus infection incidence and clearance: a systematic review of the literature. J Gen Virol. 2017.  https://doi.org/10.1099/jgv.0.000727. PubMed PMID: 28150575.
  84. 84.
    Steinberg BM, Topp WC, Schneider PS, Abramson AL. Laryngeal papillomavirus infection during clinical remission. N Engl J Med. 1983;308(21):1261–4.  https://doi.org/10.1056/NEJM198305263082104. PubMed PMID: 6302507.CrossRefPubMedGoogle Scholar
  85. 85.
    Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med. 1985;313(13):784–8.  https://doi.org/10.1056/NEJM198509263131304. PubMed PMID: 2993887.CrossRefPubMedGoogle Scholar
  86. 86.
    Pierce Campbell CM, Kreimer AR, Lin HY, Fulp W, O'Keefe MT, Ingles DJ, et al. Long-term persistence of oral human papillomavirus type 16: the HPV infection in men (HIM) study. Cancer Prev Res (Phila). 2015;8(3):190–6.  https://doi.org/10.1158/1940-6207.CAPR-14-0296. PubMed PMID: 25575501; PubMed Central PMCID: PMCPMC4355174.CrossRefGoogle Scholar
  87. 87.
    Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, et al. High oral human papillomavirus type 16 load predicts long-term persistence in individuals with or at risk for HIV infection. J Infect Dis. 2015;212(10):1588–91.  https://doi.org/10.1093/infdis/jiv273. PubMed PMID: 25954049; PubMed Central PMCID: PMCPMC4621250.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Lorenzi A, Rautava J, Kero K, Syrjanen K, Longatto-Filho A, Grenman S, et al. Physical state and copy numbers of HPV16 in oral asymptomatic infections that persisted or cleared during the six-year follow-up. J Gen Virol. 2017.  https://doi.org/10.1099/jgv.0.000710. PubMed PMID: 28100295.
  89. 89.
    Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016;126(1):5–11.  https://doi.org/10.1172/JCI85446. PubMed PMID: 26727228; PubMed Central PMCID: PMCPMC4701560.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.  https://doi.org/10.1056/NEJMoa061741. PubMed PMID: 17494925.CrossRefGoogle Scholar
  91. 91.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.  https://doi.org/10.1016/S1470-2045(11)70286-8. PubMed PMID: 22075171.CrossRefPubMedGoogle Scholar
  92. 92.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.  https://doi.org/10.1056/NEJMoa1405044. PubMed PMID: 25693011.CrossRefPubMedGoogle Scholar
  93. 93.
    Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.  https://doi.org/10.1056/NEJMoa0909537. PubMed PMID: 21288094; PubMed Central PMCID: PMCPMC3495065.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. J Infect Dis. 2016;214(8):1276–83.  https://doi.org/10.1093/infdis/jiw359. PubMed PMID: 27511896; PubMed Central PMCID: PMCPMC5034962.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8(7):e68329.  https://doi.org/10.1371/journal.pone.0068329. PubMed PMID: 23873171; PubMed Central PMCID: PMCPMC3714284.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.  https://doi.org/10.1016/j.vaccine.2012.04.108. PubMed PMID: 23199956; PubMed Central PMCID: PMCPMC4636904.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.  https://doi.org/10.1056/NEJMoa1010971. PubMed PMID: 22029979.CrossRefPubMedGoogle Scholar
  98. 98.
    Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.  https://doi.org/10.1001/jama.298.7.743. PubMed PMID: 17699008.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Saint Louis University School of MedicineSt. LouisUSA
  2. 2.Department of Otolaryngology—Head and Neck SurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of EpidemiologyJohns Hopkins University Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations